Loading...
The emergence of carbapenemases such as the Klebsiella pneumoniae carbapenemase (KPC) threatens to render carbapenems, long considered last line of defense antibiotics, ineffective. The antimicrobial development industry has responded by developing novel broader-spectrum beta lactam inhibitors to protect beta lactams like carbapenems in combined formulations. A boronic acid beta lactamase inhibitor, vaborbactam, has been combined with meropenem and approved by the U.S. FDA for the treatment of complicated urinary tract infection including pyelonephritis (cUTI/pyelo). Researchers conducted a phase 3, multinational, randomized clinical trial of meropenem-vaborbactam (MV) 2 g/2 g infused over 3 hours compared with piperacillin-tazobactam (PT) …